Document Detail


Ximelagatran for prevention and treatment of venous thromboembolism.
MedLine Citation:
PMID:  15214359     Owner:  HSR     Status:  MEDLINE    
Abstract/OtherAbstract:
Ximelagatran (Exanta (TM)) is the first oral agent in a new class of anticoagulants called direct thrombin inhibitors. Most of the available evidence regarding venous thromboembolism is from studies focusing on its prevention after major orthopedic surgery. Ximelagatran's efficacy is comparable to that of warfarin and low-molecular-weight heparin in this setting. The rates of bleeding complications for ximelagatran and its comparators were not statistically different. The elevation of liver enzymes was observed in longer term trials.
Authors:
Lisa Kwok; Michel Boucher
Related Documents :
15598259 - The practical importance of permanent and semipermanent habitats for controlling aquati...
3452359 - Preventing infant deaths: a descriptive study of one high-risk neighborhood.
19766979 - Maternal activity restriction and the prevention of preterm birth.
21730909 - Congenital central hypoventilation syndrome: a case report.
21081959 - A non-hydrolyzed, fermented milk formula reduces digestive and respiratory events in in...
21477569 - Meconium aspiration syndrome - the experience of a tertiary center.
6424639 - Intrauterine growth retardation.
8229489 - Breast-feeding of very low birth weight infants.
25123119 - Treatment of insufficient lactation is often not evidence-based.
Publication Detail:
Type:  Comparative Study; Journal Article    
Journal Detail:
Title:  Issues in emerging health technologies     Volume:  -     ISSN:  1488-6316     ISO Abbreviation:  Issues Emerg Health Technol     Publication Date:  2004 Jun 
Date Detail:
Created Date:  2004-06-23     Completed Date:  2004-07-07     Revised Date:  2010-01-22    
Medline Journal Info:
Nlm Unique ID:  100886782     Medline TA:  Issues Emerg Health Technol     Country:  Canada    
Other Details:
Languages:  eng     Pagination:  1-4     Citation Subset:  T    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Administration, Oral
Anticoagulants / adverse effects,  pharmacology,  therapeutic use*
Azetidines / adverse effects,  pharmacology,  therapeutic use*
Canada
Clinical Trials as Topic
Dose-Response Relationship, Drug
Drug Approval
Europe
Evidence-Based Medicine
Heparin, Low-Molecular-Weight / adverse effects,  pharmacology,  therapeutic use*
Humans
Orthopedic Procedures / adverse effects
Randomized Controlled Trials as Topic
Risk Factors
Venous Thrombosis / drug therapy*,  prevention & control*
Warfarin
Chemical
Reg. No./Substance:
0/Anticoagulants; 0/Azetidines; 0/Heparin, Low-Molecular-Weight; 81-81-2/Warfarin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Autonomy, guardianship and mental disorder: one problem, two solutions.
Next Document:  Laparoscopic hand-assisted pancreaticoduodenectomy: initial UK experience.